14-day Premium Trial Subscription Sign Up For FreeGet Free

Cara Therapeutics Stock Forecast NASDAQ:CARA

Price Target and Analyst Ratings

Most Recent Rating

On August 24, 2021 "Needham & Company LLC" gave "$26.00" rating for CARA. The price target was set to $15.11+5.8%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-24 $26.00 Initiated by Needham & Company LLC $14.88 $15.11+5.8%
2021-08-24 $33.00 - $35.00 Target Raised by HC Wainwright $14.88 $14.28+4.2%
2021-08-10 $26.00 Initiated by Needham & Company LLC $12.99 $13.24+5.8%
2021-08-03 $16.00 Initiated by JPMorgan Chase & Co. $11.67 $12.15+1.5%
2021-05-05 Buy Target Lowered by Needham & Company LLC $12.50 $35.00 → $26.00
2021-04-29 Buy Target Lowered by Needham & Company LLC $14.07 $35.00 → $26.00
2021-04-15 Buy Reiterated by Needham & Company LLC $28.31 $35.00
2020-09-08 Buy Reiterated by Canaccord Genuity $15.47 $30.00
2020-08-11 Buy Reiterated by Needham & Company LLC $17.43 $35.00
2020-06-18 Buy Reiterated by Needham & Company LLC $16.19 $35.00
2020-05-22 Buy Reiterated by Canaccord Genuity $16.46 $30.00
2020-05-19 Overweight Target Raised by Cantor Fitzgerald $15.24 $34.00 → $40.00
2020-04-22 Overweight Target Raised by Cantor Fitzgerald $15.71 $26.00 → $34.00
2020-04-21 Positive - Buy Target Raised by HC Wainwright $15.42 $30.00 → $33.00

CARA Stock Trend

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled.

Given the current short-term trend, the stock is expected to rise 11.54% during the next 3 months and, with a 90% probability hold a price between $13.87 and $18.30 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-23 $12.47 $14.45 $16.44
2021-09-24 $12.49 $14.48 $16.46
2021-09-27 $12.52 $14.51 $16.49
2021-09-28 $12.55 $14.53 $16.52
2021-09-29 $12.57 $14.56 $16.55
2021-09-30 $12.60 $14.59 $16.57
2021-10-01 $12.63 $14.61 $16.60
2021-10-04 $12.66 $14.64 $16.63
2021-10-05 $12.68 $14.67 $16.65
2021-10-06 $12.71 $14.69 $16.68
2021-10-07 $12.74 $14.72 $16.71
2021-10-08 $12.76 $14.75 $16.73
2021-10-11 $12.79 $14.78 $16.76
2021-10-12 $12.82 $14.80 $16.79
2021-10-13 $12.84 $14.83 $16.81
2021-10-14 $12.87 $14.86 $16.84
2021-10-15 $12.90 $14.88 $16.87
2021-10-18 $12.92 $14.91 $16.90
2021-10-19 $12.95 $14.94 $16.92
2021-10-20 $12.98 $14.96 $16.95
2021-10-21 $13.01 $14.99 $16.98
2021-10-22 $13.03 $15.02 $17.00
2021-10-25 $13.06 $15.04 $17.03
2021-10-26 $13.09 $15.07 $17.06
2021-10-27 $13.11 $15.10 $17.08
2021-10-28 $13.14 $15.13 $17.11
2021-10-29 $13.17 $15.15 $17.14
2021-11-01 $13.19 $15.18 $17.17
2021-11-02 $13.22 $15.21 $17.19
2021-11-03 $13.25 $15.23 $17.22

About Cara Therapeutics

Cara Therapeutics Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system. Its lead product candidate includes I.V. CR845, which is in Phase III clinical trials for the treatment acute postop... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT